首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1624423

2024 年至 2031 年疫苗佐剂市场（依产品类型、给药途径、疾病类型、应用及地区划分）

Vaccine Adjuvants Market By Product, By Route of Administration, By Disease Type, Application, & Region for 2024-2031

出版日期: 2024年07月11日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

疫苗佐剂市场评估，2024-2031 年

传染病流行的不断增加以及对更有效疫苗接种的需求不断增长，推动了对疫苗佐剂的需求。据 Verified Market Research 分析师称，疫苗佐剂市场规模预计将从 2023 年的约 14.8 亿美元下降至预测期内的 38.3 亿美元。

全球疫苗接种工作和对抗新兴传染病的公共卫生工作正在推动疫苗佐剂市场的成长。这将使市场从 2024 年到 2031 年的复合年增长率达到 12.68%。

疫苗佐剂市场定义/概述

疫苗佐剂是添加到疫苗中的物质，用于增强对疫苗抗原的免疫反应，从本质上提高疫苗的有效性。这些佐剂模仿通常警告免疫系统感染的危险信号和炎症，增强人体对疫苗的免疫反应。这样就可以施用更少量的抗原，从而减少需要施用的次数。

此外，疫苗佐剂的用途十分广泛，包括针对流感、肝炎等传染病的疫苗，以及治疗癌症和过敏症的疫苗。佐剂透过提高免疫反应的有效性和持久性在疫苗开发中发挥重要作用。

是什么推动了疫苗佐剂需求的激增？

全球传染病和癌症疫情的不断加剧导致对有效疫苗的需求激增。疫苗佐剂是增强疫苗免疫反应、提高疾病预防效果的重要成分。随着公共卫生工作优先考虑疫苗接种计划以控制和消除传染病，对佐剂的需求可能会增加。

製药和生技公司正在加紧研发，开发新疫苗并改进现有疫苗。这包括投资发现可以产生更强、更持久的免疫反应的新佐剂。疫苗开发创新的动力是佐剂市场的主要驱动力，各大公司都在努力提高疫苗的有效性和耐用性。

此外，世界各国政府也越来越重视疫苗接种计划，将其视为公共卫生策略的重要组成部分。这包括对疫苗（包括佐剂疫苗）的研究、开发和分发的资金。这些措施不仅可以让更多人获得疫苗，还将增加对疫苗佐剂的需求，以提高疫苗效力和接种率。

哪些因素阻碍了疫苗佐剂市场扩大？

佐剂受到严格监管，因为它们在疫苗安全性和有效性方面发挥关键作用。新佐剂的批准过程漫长而复杂，通常需要进行大规模临床试验来确认安全性和有效性。由于担心佐剂的潜在副作用和不良反应，其批准被推迟，使用也受到限制，成为市场成长的一大障碍。

疫苗佐剂市场竞争激烈，许多公司都在寻求创造独特而有效的解决方案。然而，研究、测试和生产新型佐剂的成本过高，特别是对于中小型企业而言。此外，维持疫苗价格合理以供广泛使用的需求给佐剂定价带来压力，影响获利能力和研发成本。

The rising prevalence of infectious diseases, combined with the growing need for more effective vaccinations, is driving up demand for vaccine adjuvants. According to the analyst from Verified Market Research, the vaccine adjuvants market is estimated to reach a valuation of USD 3.83 Billion over the forecast subjugating aroundUSD 1.48 Billion valued in 2023.

Global immunization efforts and public health activities to address emerging infectious illnesses are driving the growth of the vaccine adjuvants market. It enables the market to grow at aCAGR of 12.68% from 2024 to 2031.

Vaccine Adjuvants Market: Definition/ Overview

Vaccine adjuvants are substances added to vaccines to boost the immune response to the vaccine's antigen, essentially increasing their efficacy. These adjuvants mimic the danger signals and inflammation that normally alert the immune system to infections, increasing the body's immunological response to the vaccine. This allows for lower quantities of the antigen to be employed, reducing the number of doses required and perhaps making the vaccine effective for a larger segment of the population.

Furthermore, vaccine adjuvants have a wide range of applications, including usage in vaccinations for infectious diseases such as influenza and hepatitis, as well as therapeutic vaccines for cancer and allergies. Adjuvants serve an important role in vaccine development by enhancing the efficacy and duration of the immune response.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Factors that Surge the Demand for the Vaccine Adjuvants Market?

The increasing prevalence of infectious diseases and cancers around the world is resulting in a surge in demand for effective vaccines. Vaccine adjuvants are essential components that boost the immune response to vaccines, increasing their effectiveness in disease prevention. As public health initiatives prioritize vaccination programmes to manage and eradicate infectious illnesses, demand for adjuvants is likely to rise.

Pharmaceutical and biotechnology companies are ramping up their research and development efforts to create new vaccines and improve existing ones. This includes investing in the discovery of new adjuvants capable of eliciting a stronger and longer-lasting immune response. This push for innovation in vaccine development is a major driver of the adjuvants market, as companies strive to improve the efficacy and durability of their vaccines.

Furthermore, governments around the world are increasingly focusing on immunization programmes as an important component of public health strategy. This includes financing for vaccine research, development, and distribution, including those using adjuvants. Such measures not only make vaccines more accessible to a larger population, but they also increase demand for vaccine adjuvants as part of attempts to improve vaccine efficacy and coverage.

What Factors Hindering the Expansion of the Vaccine Adjuvants Market?

Due to their vital role in vaccine safety and efficacy, adjuvants are regulated closely. The approval procedure for new adjuvants is lengthy and complicated, frequently requiring significant clinical trials to verify safety and efficacy. Concerns about potential side effects or adverse reactions to adjuvants cause delays in approval or limitations in use, posing a significant impediment to market growth.

The vaccine adjuvants market is fiercely competitive, with many businesses seeking to create unique and effective solutions. However, the expense of researching, testing, and manufacturing novel adjuvants is excessively expensive, especially for small businesses. Furthermore, the requirement to maintain vaccinations affordable for widespread use puts pressure on adjuvant pricing, which affects profitability and R&D expenditure.

Category-Wise Acumens

How does the Particulate Adjuvant Segment Impact the Growth of the Vaccine Adjuvants Market?

According to VMR analysis, the particulate adjuvant segment is estimated to hold the largest market share during the forecast period. Particulate adjuvants are very effective at increasing the immunological response to vaccines. They mirror the size and structure of infections, allowing the immune system to recognize and respond more effectively to vaccine antigens. This feature makes particle adjuvants particularly useful in the creation of vaccines for diseases that require a strong and long-lasting immune response to be successful.

Particulate adjuvants are highly versatile and compatible with a wide range of vaccines, including subunit, recombinant, conjugate, and inactivated vaccines. Because of their broad compatibility, they can be used in a variety of vaccines, which increases their adoption and market share. Also, their ability to be customized with specific qualities, such as size, charge, and surface modification, allows for the development of more focused and effective vaccination formulations.

Furthermore, advances in nanotechnology and materials science have considerably improved particulate adjuvant design and manufacture. These technical advancements have resulted in the production of nanoparticles and microparticles that can be carefully tailored to optimize adjuvant qualities, such as improving mucosal immunity or targeting specific immune system cells. Particulate adjuvant technology's potential uses are expanding as a result of continued research and innovation, consolidating its market dominance.

How do Commercial Applications of Vaccine Adjuvants Drive the Demand?

The commercial application segment is estimated to dominate the vaccine adjuvants market during the forecast period. Vaccination programmes have increased significantly over the world, spurred by efforts by both governments and non-governmental organizations to combat infectious illnesses and avoid epidemics. These programmes frequently necessitate huge amounts of vaccinations for general public usage, which directly increases the demand for vaccine adjuvants used in commercial vaccine manufacturing. The desire for increased immunization rates against influenza, COVID-19, HPV, and other diseases emphasizes the importance of effective vaccine adjuvants in commercial applications.

Furthermore, preventive healthcare treatments, such as vaccination for adults and the elderly, are becoming more popular to combat age-related susceptibility to infectious diseases and minimize healthcare expenses. The commercial sector has responded by creating and marketing vaccinations intended specifically for these populations, with adjuvants used to boost vaccine efficacy. This tendency helps to explain why commercial uses dominate the vaccination adjuvants market.

Country/Region-wise Acumens

Will Flourishing Pharmaceutical Sector Drive the Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the vaccine adjuvants market during the forecast period. North America, particularly the United States, has a well-developed healthcare system and devotes a considerable portion of its GDP to healthcare spending. This involves significant spending in R&D, vaccine manufacture, and immunisation programmes. The advanced healthcare infrastructure enables considerable vaccine research and development efforts, allowing for the rapid acceptance and integration of new vaccine adjuvants into vaccination programmes.

Furthermore, North America is home to some of the world's biggest pharmaceutical and biotechnology businesses, which play an important role in the global vaccination industry. These firms make significant investments in the research of novel vaccines and adjuvant technology, helping the area maintain its leadership in the vaccine adjuvants industry. Their efforts in innovation, together with strong pipelines for vaccine development, assure a consistent demand for vaccine adjuvant.

How will Increasing Healthcare Services in Asia Pacific Boost the Market?

The Asia Pacific region is estimated to grow at the highest CAGR during the forecast period. Asia-Pacific is characterized by its large and quickly growing population, which creates an increased demand for healthcare services, particularly immunization. As countries in this region continue to develop economically, there is a greater emphasis on strengthening healthcare infrastructure and access to preventive healthcare services like vaccination. This demographic and economic shift fuels the demand for vaccines and, by extension, vaccine adjuvants.

Furthermore, many governments in Asia-Pacific have been actively adopting and expanding national immunization programmes. These projects, which aim to increase immunization coverage in the population, frequently receive significant money and policy backing. Such government support not only enhances the vaccine market directly but also promotes the research and use of vaccine adjuvants, which are an essential component of effective vaccinations.

Competitive Landscape

The competitive landscape of the vaccine adjuvants market is dynamic and evolving, with competitors constantly striving to innovate and extend their product portfolios to suit the growing demand for more effective and less reactogenic vaccines.

Some of the prominent players operating in the vaccine adjuvants market include:

GlaxoSmithKline, Dynavax Technologies, Novavax, Croda International, Seppic, Merck KGaA, CSL Limited, InvivoGen, Pfizer, AstraZeneca, SPI Pharma, Agenus Inc, Phibro Animal Health Corporation, Vertellus, Allergy Therapeutics, Vaxine Pty Ltd, CureVac AG.

Latest Developments

In May 2021, CSL supported the State Government Budget's pledge to develop an Identity Box to encourage maritime trade and Australian medical research. The Patent Box strategy will encourage local manufacture of novel medical items while also combating the eradication of Australian intellectual property (IP) and highly skilled jobs.

1 INTRODUCTION OF GLOBAL VACCINE ADJUVANTS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VACCINE ADJUVANTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT

5.1 Overview
5.2 Pathogen
5.3 Adjuvants Emulsions
5.4 Pathogen Components
5.5 Saponin-based Adjuvants
5.6 Particulate Adjuvants
5.7 Other Adjuvants

6 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

6.1 Overview
6.2 Intradermal
6.3 Subcutaneous
6.4 Others

7 GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE TYPE

7.1 Overview
7.2 Infectious Diseases
7.3 Cancer
7.4 Others

8 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION

8.1 Overview
8.2 Research Applications
8.3 Commercial Applications

9 GLOBAL VACCINE ADJUVANTS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL VACCINE ADJUVANTS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 GlaxoSmithKline
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Dynavax Technologies
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Novavax
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Croda International
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Seppic
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Merck KGaA
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 CSL Limited
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 InvivoGen
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Pfizer
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 AstraZeneca
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments